Background: Switching to a second tumour necrosis factor inhibitor (TNFi) after discontinuation of a first in rheumatoid arthritis (RA) is a common strategy. The reason for the switch from the first TNFi could potentially influence the response to therapy. Data on direct comparisons between TNFi after switching are limited.
Methods: The national Swedish register was used. RA patients who switched to a second TNFi (infliximab, etanercept or adalimumab) after failure of a TNFi as first-ever biologic were identified. Effectiveness of treatment was compared across the three drugs according to the first TNFi used, the reason for discontinuing and the drug survival. Drug survival across TNFi used as second biologic was compared.
Results: Half of all patients starting infliximab, adalimumab or etanercept during the period 2005-2012 discontinued treatment for various reasons. Of these patients, a third switched within 2 months to a second TNFi (infliximab, etanercept or adalimumab). Around 35% of all patients achieved low disease activity or remission at 6 months. Regarding the switching strategy, best results were observed among patients who switched from infliximab to etanercept because of (secondary) inefficacy. Etanercept as second TNFi was associated with longer drug survival compared with infliximab.
Conclusions: Switching to a second TNFi after the failure of the first may lead to good clinical results. The inter-drug differences in drug survival on the second TNFi mirror those reported previously for the first TNFi, suggesting that these differences are not solely due to channelling bias.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/annrheumdis-2013-204714 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expert Clinical Management of Inflammatory Immune-Related Arthritis in Patients with Cancer Receiving Immune Checkpoint Inhibitors.
J Immunother Precis Oncol
February 2025
Department of Health Services and Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Introduction: Treatment guidelines for immune-related inflammatory arthritis (irAE-IA) in patients with cancer receiving immune checkpoint inhibitors (ICIs) are vague with respect to the use of specific agents. Patients are usually referred to rheumatologists for treatment. We conducted a survey of expert rheumatologists to determine current practices.
View Article and Find Full Text PDFEfficacy and Safety of CT-P13 as First- and Second-Line Treatment in Patients with Ankylosing Spondylitis.
J Clin Med
November 2024
Division of Rheumatology, School of Medicine, Dokuz Eylul University, 35220 Izmir, Turkey.
CT-P13 is a biosimilar version of infliximab, a monoclonal antibody. In individuals with ankylosing spondylitis (AS), CT-P13 has been shown to be effective and to have a well-tolerated safety profile. The aim of this study was to evaluate the long-term drug persistence, safety, and efficacy of infliximab biosimilar CT-P13 in patients with AS undergoing first-line (1st-line) and later (≥2nd-line) treatment in clinical practice.
View Article and Find Full Text PDFTNFα-inhibitors cycling with golimumab as second drug in inflammatory arthritis patients: Data from the multicenter GO-REAL registry.
Reumatol Clin (Engl Ed)
December 2024
Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina. Electronic address:
Article Synopsis
- This study evaluated the effectiveness and persistence of golimumab (GLM) in patients with rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis who previously used other TNF inhibitors compared to those who haven't.
- A total of 192 patients were included, with follow-up results indicating that the majority discontinued GLM due to inefficacy, and the median survival for GLM treatment was similar for both experienced and naive patients.
- The study concluded that prior TNFi experience did not significantly affect the survival or persistence of GLM treatment, but having public health insurance was linked to higher discontinuation rates.
The Retention Rate and Safety of Secukinumab as a First-Line Biologic Agent in Axial Spondyloarthritis Compared to a First Tumor Necrosis Factor (TNF) Inhibitor: A Real-World, Longitudinal Study.
Cureus
September 2024
Department of Rheumatology A, El Ayachi Hospital, Ibn Sina University Hospital, Salé, MAR.
Background and objective Secukinumab (SECU) is a biologic disease-modifying antirheumatic drug (bDMARD) that has demonstrated effectiveness against axial spondyloarthritis (ax-SpA). However, in clinical practice, secukinumab is most commonly used as a second-line treatment after failure of or intolerance to tumor necrosis factor inhibitors (TNFi). In this study, we aimed to compare the two-year drug retention between secukinumab and TNFi in biologic-naïve patients with ax-SpA, to estimate the remission/low disease activity (LDA) rates in both groups and assess the safety profiles.
View Article and Find Full Text PDFInfections in psoriatic arthritis: association with treatment.
Ther Adv Musculoskelet Dis
October 2024
Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, Second Department of Medicine and Laboratory, National and Kapodistrian University of Athens School of Medicine, General Hospital of Athens Hippokration, 114 Vass. Sophias Avenue, Athens 115 27, Greece.
Article Synopsis
- - Serious infections (SIs) are a major concern for patients with psoriatic arthritis (PsA), especially when treated with various medications, including traditional options like methotrexate and newer biologics such as IL-23 inhibitors and JAK inhibitors.
- - While the overall incidence of SIs in PsA patients is lower than that in rheumatoid arthritis patients, there are ongoing safety concerns, particularly with the potential reactivation of latent infections like tuberculosis when using TNF inhibitors, which can be managed with proper screening.
- - Newer treatments like IL-23 inhibitors show no increase in common infection risk, but JAK inhibitors are associated with an elevated risk of herpes zoster, highlighting the importance of monitoring and preventive measures in treatment
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!